PNA FISH® Test Reporting Dramatically Decreases Mortality and Hospital Costs
A new study documents significant decreases in ICU mortality and hospital costs for patients with bloodstream infections after implementation of PNA FISH tests for rapid identification of bloodstream pathogens. The study was performed at The University of Arizona Medical Center - University Campus (Tucson, Arizona) in a collaboration between the clinical microbiology laboratory and infectious diseases pharmacists as part of the institution's Antimicrobial Stewardship Program. Results were presented at the recently concluded 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) in Chicago.1
The retrospective study (pre-PNA FISH vs. post-PNA FISH intervention) assessed the clinical and financial impact of laboratory testing and reporting of PNA FISH results to guide therapeutic intervention by infectious diseases pharmacists and physicians using established treatment algorithms. The study included patients with positive blood cultures admitted to the medical center between August 2007 and March 2011. A total of 460 patients with results indicative of enterococcal or streptococcal bacteremia, i.e., Gram-positive cocci in pairs and chains (GPCPC) from positive blood cultures, were included in the study. Of these patients, 262 had PNA FISH performed. A total of 125 patients with yeast-positive blood cultures, indicative of candidemia, were also included, of which 82 had PNA FISH performed.
Significant Study Findings
'The study clearly demonstrates that implementing and active reporting of rapid diagnostic tests like PNA FISH can have a real impact on improving outcomes and the cost of care for patients with bloodstream infections. That's a win-win situation for patients, healthcare providers and the healthcare system overall' said Thais T. Johansen, President and CEO of AdvanDx. 'We are very proud of the contribution PNA FISH can make in helping hospitals improve the quality and efficiency of care and we greatly appreciate the work that Dr. Wolk and her colleagues at The University of Arizona Medical Center have performed in demonstrating those benefits.'
Every year, more than 875,000 patients are diagnosed with bloodstream infections in the United States. The infections are associated with high mortality rates and increased healthcare costs.2,3 The infections can be difficult to treat as conventional diagnostic methods can take days and clinicians have to balance prescribing early, effective therapy while avoiding prolonged exposure to broad-spectrum antibiotics in the face of increasing antibiotic resistance. PNA FISH® is a rapid, molecular diagnostic platform that provides pathogen identification directly from positive blood cultures in just 90 minutes. PNA FISH tests enable microbiology labs to report pathogen results 2 to 3 days sooner than conventional methods and thereby help clinicians optimize antibiotic therapy earlier for patients with bloodstream infections.
1. Gamage DC, D.P. Olson DP, Stickell LH, Matthias KR, Tuttle EC, Johnson DR, Valentino C, Nix DE, Whitfield NN, Wolk DM. Significant Decreases in Mortality and Hospital Costs After Laboratory Testing with PNA FISH®. Poster D-1302b. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011). Chicago, Illinois, USA.
2. Al-Rawajfah et al. Incidence of and Risk Factors for Nosocomial Bloodstream Infections in Adults in the United States. Infect. Control Hosp Epedimiol. 2009 Nov; 30(11):1036-44
3. Wier et al. Diagnostic Groups with Rapidly Increasing Costs, by Payer, 2001-2007. HCUP Statistical Brief #91. 2010 June; Agency for Healthcare Research and Quality, Rockville, MD.
Source: AdvanDx View latest company information
Posted: October 14, 2011
[will open your email client]